Investigation of the safety of Radium-223 chloride in combination with external beam radiotherapy for bone metastases of prostate cancer.

ABSTRACT: This study aimed to investigate the safety of combining radium-223 chloride (Ra-223) therapy with external beam radiation therapy (EBRT) for patients with multiple bone metastases from castration-resistant prostate cancer (CRPC), including lesions requiring urgent treatment such as those causing neurological symptoms due to spinal cord compression. We retrospectively analyzed data from patients with CRPC and bone metastases treated with Ra-223 therapy at our hospital between September 1, 2018, and December 31, 2023. Adverse events were evaluated using the Common Terminology Criteria for Adverse Events version 4.0. Of the 23 patients referred, data from 17 were included; 8 received concurrent Ra-223 therapy and EBRT, whereas others received only Ra-223 therapy. The median follow-up period w

SUBMITTER: Makino S 

PROVIDER: S-EPMC11932343 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature